Dataset Information

Phosphoproteome of MCF7 breast cancer cells treated with estradiol and BI2536

ABSTRACT: Triple SILAC phosphoproteome experiment of hormone deprived MCF7 cells treated with estradiol (E2) in presence or absence of the PLK1 inhibitor BI2536. Conditions were as follows: light (L) population: 1h DMSO, 30min EtOH; medium (M) population: 1h DMSO, 30min E2; heavy (H) population: 1h BI2536, 30min E2. Biological replicates: A and B. Phosphopeptides were enriched from soluble and insoluble fraction using a two step enrichment protocol consiting of strong cation exchange and TiO2 affinity chromatography. The peptides were analyzed on an Orbitrap Velos mass spectrometer linked to an online nanoflow HPLC system via a nanoelectrospray ion source and fragmented via higher-energy C-trap dissociation (HCD). Analysis was carried out using MaxQuant (v. 1.2.2.5) with standard settings including STY phosphporylation as variable modification.

OTHER RELATED OMICS DATASETS IN: PRJNA202861

INSTRUMENT(S): LTQ Orbitrap Velos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Breast Cancer Cell

SUBMITTER: Michael Wierer

LAB HEAD: Miguel Beato

PROVIDER: PXD000275 | Pride | 2016-06-24

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	061010_Michael_Beato_P1.raw	Raw
	061010_Michael_Beato_P1a.raw	Raw
	061010_Michael_Beato_P1b.raw	Raw
	061010_Michael_Beato_P2_reinj.raw	Raw
	061010_Michael_Beato_P3_reinj.raw	Raw

Items per page:

1 - 5 of 124

Publications

PLK1 signaling in breast cancer cells cooperates with estrogen receptor-dependent gene transcription.

Wierer Michael M Verde Gaetano G Pisano Paola P Molina Henrik H Font-Mateu Jofre J Di Croce Luciano L Beato Miguel M

Cell reports 20130613 6

Polo-like kinase 1 (PLK1) is a key regulator of cell division and is overexpressed in many types of human cancers. Compared to its well-characterized role in mitosis, little is known about PLK1 functions in interphase. Here, we report that PLK1 mediates estrogen receptor (ER)-regulated gene transcription in human breast cancer cells. PLK1 interacts with ER and is recruited to ER cis-elements on chromatin. PLK1-coactivated genes included classical ER target genes such as Ps2, Wisp2, and Serpina3 ...[more]

PMID: 23770244

Similar Datasets

Project description:17β-estradiol (E2) is an important endocrine hormone underlying mammalian body, which participates in the regulatory of physiological functions of reproductive system, mammary gland, bone and cardiovascular, et.al. Paradoxically, despite the physiological actions of endogenous E2 (0.2-1.0 nmol/L), numerous clinical and experimental studies demonstrated that high-dose E2 treatment could cause tumor regression and exert pro-apoptotic actions in multiple cells, but the underlying mechanism is still undescribed. Especially, little information of cellular processes responding to lethality of 17β-estradiol is available. In the present work, we attempted to characterize the cellular processes responding to high-dose (mol/L) E2 treatment by quantitative phosphoproteomics to help understand the regulatory mechanism of E2 induced cell death. Therefore, to analyze the cell phenotype induced by high-dose (umol/L) E2, cell counting kit-8 assay (CCK8), cell cytotoxicity analysis by trypan blue staining and microscopy imaging were first performed on HeLa cells following 1-10 mol/L E2 or dimethyl sulfoxide (DMSO) treatment for 1-3 days. As a result, E2 was found to inhibit cell proliferation and induce cell death in a dose-dependent and time-dependent fashion. Specially, in comparison with DMSO-treated HeLa cell samples, 5 umol/L E2 treatment for 2 days resulted in > 74% of growth inhibition and about 50% of cell death, which was employed for following quantitative phosphoproteomic analysis. To investigate the intracellular cellular processes responding to high-dose (umol/L) E2 treatment, solid phase extraction (SPE)-based immobilized titanium ion affinity chromatography (Ti-IMAC) phosphopeptide enrichment method coupled with data independent acquisition (DIA)-based quantitative proteomics was employed for in-depth screening of high-dose E2 regulated phosphorylation sites. As a result, more than 10000 phosphorylation sites were identified from the E2 and DMSO treated HeLa cell samples by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Among these phosphorylation sites, in comparison with the DMSO-treated cell samples, 5 umol/L E2 treatment caused an increase of 537 phosphorylation sites on 372 proteins and a decrease of 387 phosphorylation sites on 256 proteins with a threshold of p-value < 0.01 and |fold change|≥2. Totally 924 phosphorylation sites on 599 proteins were significantly regulated by high-dose (umol/L) E2, which were then performed for enrichment analysis. In addition, 453 phosphorylation sites on 325 proteins were found to be identified in only E2 or DMSO treated cell samples. These phosphorylation sites probably be phosphorylated or de-phosphoylated responding to high-dose E2 stimulation, which likely be regulated by high-dose (umol/L) E2 and were also performed for enrichment analysis in parallel. Taken together, 1218 phosphorylation sites on 741 proteins were significantly regulated by high-dose E2.

Project description:Multiple signaling pathways ultimately modulate the epigenetic information embedded in the chromatin of gene promoters by recruiting epigenetic enzymes. We found that, in estrogen-regulated gene programming, the acetyltransferase CREB-binding protein (CBP) is specifically and exclusively methylated by the coactivator-associated arginine methyltransferase (CARM1) in vivo. CARM1-dependent CBP methylation and p160 coactivators were required for estrogen-induced recruitment to chromatin targets. Notably, methylation increased the histone acetyltransferase (HAT) activity of CBP and stimulated its autoacetylation. Comparative genome-wide chromatin immunoprecipitation sequencing (ChIP-seq) studies revealed a variety of patterns by which p160, CBP, and methyl-CBP (meCBP) are recruited (or not) by estrogen to chromatin targets. Moreover, significant target gene-specific variation in the recruitment of (1) the p160 RAC3 protein, (2) the fraction of a given meCBP species within the total CBP, and (3) the relative recruitment of different meCBP species suggests the existence of a target gene-specific âfingerprintâ for coregulator recruitment. Crossing ChIP-seq and transcriptomics profiles revealed the existence of meCBP âhubsâ within the network of estrogen-regulated genes. Together, our data provide evidence for an unprecedented mechanism by which CARM1-dependent CBP methylation results in gene-selective association of estrogen-recruited meCBP species with different HAT activities and specifies distinct target gene hubs, thus diversifying estrogen receptor programming. Examination of estrogen-induced binding site in H3396 cells under Estrogen (E2) or Ethanol (EtOH) treatment: CBP in E2; CBP in EtOH (two technical replicate); CBPR742m in E2 (two technical replicates); CBPR768m in E2; CBPR768m in EtOH; CBPR2151m in E2; CBPR2151m in EtOH; Estrogen receptor alpha (ERa) in E2; ERa in EtOH; Total Histone 3 and 4 acetylated in E2; H3K18ac in E2; H3K18ac in EtOH; Polymerase II (PolII) in E2; PolII in EtOH; RAC3 in E2; Input DNA sample in E2